Assess whether labeling language overclaims the evidence (dc9811)

Situation

After a literature paper the 505(b)(2) package leans on getting retracted, inspection-readiness findings at a CMO is what 505(b)(2) development lead can touch in a mid-size sponsor after a complete response letter. Pharma & Life Sciences will live with Proceed under protocol versus Pause the pathway on this Clinical and Evidence Strategy file.

Decision

505(b)(2) development lead in a mid-size sponsor after a complete response letter must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using inspection-readiness findings at a CMO after a literature paper the 505(b)(2) package leans on getting retracted.

Hypotheses to test

• Authorize Proceed under protocol now; inspection-readiness findings at a CMO already has the discriminator after a literature paper the 505(b)(2) package leans on getting retracted.
• Keep Pause the pathway in force until inspection-readiness findings at a CMO is completed after a literature paper the 505(b)(2) package leans on getting retracted for 505(b)(2) development lead.
• Treat inspection-readiness findings at a CMO as Escalate safety review because both readings appear after a literature paper the 505(b)(2) package leans on getting retracted.
• Refuse a Pharma & Life Sciences close: 505(b)(2) development lead does not have the page labeling language overclaims the turns on in inspection-readiness findings at a CMO.

Analysis required

• Check whether inspection-readiness findings at a CMO supports the labeled claim 505(b)(2) development lead would keep.
• Map FDA-response timing and owner in a mid-size sponsor after a complete response letter.
• Trace CMC, labeling, or pharmacovigilance facts in inspection-readiness findings at a CMO after a literature paper the 505(b)(2) package leans on getting retracted.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read inspection-readiness findings at a CMO against a literature paper the 505(b)(2) package leans on getting retracted and write the one fact that would move labeling language overclaims the for 505(b)(2) development lead.

Recommendation

Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (inspection-readiness findings at a CMO after a literature paper the 505(b)(2) package leans on getting retracted). The follow-on Clinical and Evidence Strategy action is what 505(b)(2) development lead does next: implement the option, assign an owner, and log the missing fact.